A question for those more statistically minded.
Our phase 1 on 12 patients has a p 0.11 for the second cohort, meaning 89% certainty the results are because of the drug. In trials statistical significance starts at p 0.05 meaning 95% certainty.
My question is can any insight at all be gained from the p 0.11 and the Berry stats to give higher level of certainty that a phase 2 will be successful. I'm guessing probably not, but curious if anyone has stumbled on any studies that link the p value in a phase 1 to the p value in a subsequent phase 2.
My guess is, it gives some confidence, but there are way too many dependents on a sample size 15 to 20x bigger. The results could land absolutely anywhere.
Just musing how the p values translate across sample sizes etc, if at all.
A question for those more statistically minded.Our phase 1 on 12...
-
- There are more pages in this discussion • 473 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $92.38M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.5¢ | $70.59K | 380.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 220000 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 89682 | 4 |
View Market Depth
| Last trade - 10.42am 05/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |